Ac-VFAQ-OH

Rif. 3D-PP45352

Informazioni sul prodotto

• Nome: Ac-VFAQ-OH
• Sinonimi: Ac-Val-Phe-Ala-Gln-OH

Descrizione

Peptide Ac-VFAQ-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using Ac-VFAQ-OH include the following: Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia Z Awan , A Baass , J Genest - Clinical chemistry, 2014 - academic.oup.comhttps://academic.oup.com/clinchem/article-abstract/60/11/1380/5621718 Potential opportunity in the development of new therapeutic agents based on endogenous and exogenous inhibitors of the proprotein convertases Y Bontemps, N Scamuffa, F Calvo - Medicinal Research , 2007 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/med.20072 Inhibitory feature of the proprotein convertases prosegments Y Bontemps, M Lapierre, G Siegfried , F Calvo - Medicinal , 2008 - researchgate.nethttps://www.researchgate.net/profile/Marion-Lapierre/publication/5516648_Inhibitory_Feature_of_the_Proprotein_Convertases_Prosegments/links/5406f58c0cf2bba34c1e7d16/Inhibitory-Feature-of-the-Proprotein-Convertases-Prosegments.pdf Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? Y Banerjee , RD Santos , K Al-Rasadi , M Rizzo - Atherosclerosis, 2016 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0021915016300612 GALNT2 regulates ANGPTL3 cleavage in cells and in vivo of mice X Li, Y Zhang, M Zhang, Y Wang - Scientific Reports, 2020 - nature.comhttps://www.nature.com/articles/s41598-020-73388-3 The Multifaceted Furin-like Proprotein Convertases: Defining their in vivo roles in physiological models WJ Kim - 2016 - search.proquest.comhttps://search.proquest.com/openview/6ac57923b27f474d81d6a08b274fa34c/1?pq-origsite=gscholar&cbl=18750&diss=y Development of enhanced furin inhibitors with reduced toxicity as potential broad spectrum antiviral drugs Entwicklung optimierter Furinhemmstoffe mit reduzierter W mit breitem Wirkungsspektrum - archiv.ub.uni-marburg.dehttps://archiv.ub.uni-marburg.de/diss/z2021/0510 Relative expression of proprotein convertases in rat ovaries during pregnancy SCM Kwok, D Chakraborty , MJ Soares - Journal of Ovarian , 2013 - Springerhttps://link.springer.com/article/10.1186/1757-2215-6-91 Proprotein convertase inhibitory activities of flavonoids isolated from Oroxylum indicum S Majumdar, BC Mohanta - Current medicinal , 2010 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cmc/2010/00000017/00000019/art00004 LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation RH Alghamdi, P O'Reilly, C Lu, J Gomes - European journal of , 2015 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0223523415000422 The biology and therapeutic targeting of the proprotein convertases NG Seidah , A Prat - Nature reviews Drug discovery, 2012 - nature.comhttps://www.nature.com/articles/nrd3699 The multifaceted biology of PCSK9 NG Seidah , A Prat - Endocrine Reviews, 2022 - academic.oup.comhttps://academic.oup.com/edrv/article-abstract/43/3/558/6385885 The proprotein convertases, 20 years later NG Seidah - Proprotein Convertases, 2011 - Springerhttps://link.springer.com/protocol/10.1007/978-1-61779-204-5_3 Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells MC McNutt, TA Lagace, JD Horton - Journal of Biological Chemistry, 2007 - ASBMBhttps://www.jbc.org/article/S0021-9258(20)54765-0/abstract The role of proprotein convertases in the regulation of the function of immune cells in the oncoimmune response M Rose , M Duhamel , F Rodet, M Salzet - Frontiers in Immunology, 2021 - frontiersin.orghttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.667850/full Mutation in the PCSK9 gene in Omani Arab subjects with autosomal dominant hypercholesterolemia and its effect on PCSK9 protein structure K Al-Waili , WAM Al-Zidi, AR Al-Abri - Oman medical , 2013 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3562979/ Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell J Mayne , T Dewpura, A Raymond, L Bernier - Clinical , 2011 - academic.oup.comhttps://academic.oup.com/clinchem/article-abstract/57/10/1415/5621266 Molecular basis for LDL receptor recognition by PCSK9 HJ Kwon, TA Lagace, MC McNutt - Proceedings of the , 2008 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.0712064105 Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the brain and relevance for neuropsychiatric disorders EM O'Connell, FW Lohoff - Frontiers in neuroscience, 2020 - frontiersin.orghttps://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00609 Regions of conformational flexibility in the proprotein convertase PCSK9 and design of antagonists for LDL cholesterol lowering D Kirchhofer, DJ Burdick, NJ Skelton - Biochemical Society , 2020 - portlandpress.comhttps://portlandpress.com/biochemsoctrans/article-abstract/48/4/1323/226077 Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia D Cunningham , DE Danley, KF Geoghegan - Nature structural & , 2007 - nature.comhttps://www.nature.com/articles/nsmb1235 Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels-experimental and clinical approaches with lipid-lowering agents C Macchi, M Banach , A Corsini - European Journal of , 2019 - academic.oup.comhttps://academic.oup.com/eurjpc/article-abstract/26/9/930/5926000 Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer A Bhattacharya , A Chowdhury, K Chaudhury - et Biophysica Acta (BBA , 2021 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0304419X21000780 C2-Symmetric azobenzene-amino acid conjugates and their inhibition of Subtilisin Kexin Isozyme-1 A Basak, D Mitra, AK Das , D Mohottalage - Bioorganic & medicinal , 2010 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0960894X10005718

• Marchio: Biosynth